Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.42 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.40 |
| ▸ | THRA | P10827 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11751290 | 1.00 | LMNA (0.55) | LMNASLC1A3SLC1A2SLC1A1PARP15 | |
| SCHEMBL3677140 | 0.98 | LMNA (0.52) | LMNASLC1A3SLC1A2SLC1A1PARP15 | |
| SCHEMBL2590590 | 0.93 | — | — | |
| SCHEMBL2966870 | 0.88 | — | — | |
| SCHEMBL2265196 | 0.88 | LMNA (0.41) | LMNASLC1A3SLC1A2SLC1A1PARP15 | |
| SCHEMBL1669840 | 0.81 | LMNA (0.59) | LMNASLC1A3SLC1A2SLC1A1PARP15 | |
| SCHEMBL23129641 | 0.79 | LMNA (0.57) | LMNASLC1A3SLC1A2SLC1A1PARP15 | |
| SCHEMBL1864716 | 0.79 | LMNA (0.62) | LMNASLC1A3SLC1A2SLC1A1PARP15 | |
| SCHEMBL4631096 | 0.79 | LMNA (0.62) | LMNASLC1A3SLC1A2SLC1A1PARP15 | |
| SCHEMBL8393247 | 0.79 | LMNA (0.57) | LMNASLC1A3SLC1A2SLC1A1PARP15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119059951-A | Process for preparing peroxyesters or peroxycarbonates | 诺力昂化学品国际有限公司 | 2024-12-03 | — | — | CN | claimed |
| CN-108276386-B | Cyclohexyl methoxy formyl amino quinazoline compound and preparation and application thereof | 浙江工业大学 | 2020-10-09 | — | — | CN | claimed |
| US-20250376452-A1 | 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use Thereof | ENANTA PHARM INC (US) | 2025-12-11 | — | — | US | disclosed |
| WO-2025224262-A1 | COMBINATION THERAPIES COMPRISING A CDK2 DEGRADER AND A CDK4/6 INHIBITOR | MONTE ROSA THERAPEUTICS AG (CH) | 2025-10-30 | — | — | WO | disclosed |
| EP-4608816-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | Monte Rosa Therapeutics AG (CH) | 2025-09-03 | — | — | EP | disclosed |
| US-20250263395-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-21 | — | — | US | disclosed |
| US-12384753-B2 | 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2025-06-26 | — | — | US | disclosed |
| EP-4499612-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2025-02-05 | — | — | EP | disclosed |
| CN-119059951-A | Process for preparing peroxyesters or peroxycarbonates | 诺力昂化学品国际有限公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-118974020-A | Substituted 3-aminoindazole derivatives as kinase inhibitors | 内尔维亚诺医疗科学公司 | 2024-11-15 | — | — | CN | disclosed |
| US-5559232-A | ANTICOAGULANTS | HOFFMANN-LA ROCHE INC. (US) | 1996-09-24 | — | — | US | disclosed |
| US-5444068-A | Imidazopyridine derivatives as angiotensin II receptor antagonists, pharmaceuticals, and treatment of hypertension therewith | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-08-22 | — | — | US | disclosed |
| US-5426190-A | Preparation of N-(organocarbonyloxy)-succinimide derivatives of N-hydroxysuccinimide | PPG INDUSTRIES, INC. (US) | 1995-06-20 | — | — | US | disclosed |
| US-4859229-A | HERBICIDES | HOFFMANN-LA ROCHE INC. (US) | 1989-08-22 | — | — | US | disclosed |
| US-4661145-A | HYDRIDIZATION AGENTS | ROHM AND HAAS COMPANY (US) | 1987-04-28 | — | — | US | disclosed |
| US-4515787-A | Steroids | ROUSSEL UCLAF (FR) | 1985-05-07 | — | — | US | disclosed |
| US-4415571-A | HYPOTENSIVE AGENTS; THROMBOSIS; ANTICOAGULANTS; CARDIOVASCULAR DISORDDERS | BASF AKTIENGESELLSCHAFT (DE) | 1983-11-15 | — | — | US | disclosed |
| US-4345934-A | Method of producing hybrid cereal grain seeds by application of 1-aryl-1,4-dihydro-4-oxo(thio)-pyridazines | ROHM AND HAAS COMPANY (US) | 1982-08-24 | — | — | US | disclosed |
| US-3939265-A | MIXTURE OF AN ANABOLISANT AND ESTROGENIC STEROID | GRANDADAM JEAN ANDRE | 1976-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | CDK1, CDK11A, CDK3 | LMNA 1723/4885SLC1A3 3122/4885SLC1A2 3927/4885 |
| US-20250376452-A1 | 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use Thereof | HSD17B1, HSD17B13, HSD17B3 | LMNA 2111/4885SLC1A3 2157/4885SLC1A2 3176/4885 |
| US-12384753-B2 | 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof | HSD17B1, HSD17B13, HSD17B3 | LMNA 2111/4885SLC1A3 2157/4885SLC1A2 3176/4885 |
| US-20250263395-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | CDK2, SKP2, CDK1 | LMNA 2140/4885SLC1A3 4485/4885SLC1A2 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.